Top Markets
Coin of the day
Fennec Pharmaceuticals Inc. Fennec Pharmaceuticals Inc.

Fennec Pharmaceuticals Inc.

FENC
Rangering i aksjer #14209
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical firm. Its leading... Fennec Pharmaceuticals Inc. operates as a biopharmaceutical firm. Its leading investigational drug in clinical development is PEDMARK, a specialized formulation of sodium thiosulfate. This treatment is designed to shield young cancer patients from hearing damage (ototoxicity) that can be induced by platinum-based chemotherapy. The company, which was founded in 1996, previously operated under the name Adherex Technologies Inc. before officially rebranding as Fennec Pharmaceuticals Inc. in September 2014. Its corporate headquarters are situated in Research Triangle Park, North Carolina.
Aksjekurs
$12.33
Sist synkronisert: 2026-08-31
Markedsverdi
$428.31M
Endring (1 dag)
0.49%
Endring (1 år)
39.01%
Land
US
Handel Fennec Pharmaceuticals Inc. (FENC)

Kategori

Inntekter for Fennec Pharmaceuticals Inc. (FENC)
Inntekter i 2026 TTM: 0
Ifølge Fennec Pharmaceuticals Inc. sine nyeste økonomiske rapporter er selskapets nåværende resultat 0. I 2026 hadde selskapet et resultat på 0, lik resultatet i 2026, som var 0. Resultatet som vises på denne siden er resultat før renter og skatt, eller EBIT.
Inntektshistorikk for Fennec Pharmaceuticals Inc. fra 2026 til 2026
Inntekter ved slutten av hvert år
År Inntekter Endre
Ikke nok data for de angitte datoene.
Inntekter for lignende selskaper eller konkurrenter
Selskap Inntekter Forskjell i inntekter Land
$5.27B -
US
$1.95B -
NL
$-4.02B -
AU
$-3.09B -
US
- -
CH